Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Adebrelimab + Regorafenib in Advanced HCC After Immunotherapy Failure
NCT06375317Phase 2Not yet recruiting
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab, regorafenib in hepatocellular carcinoma (HCC). Planned start Apr 2024; status: not yet recruiting.
02
Drugs
adebrelimabregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06375317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375317.